potassium chloride has been researched along with Abnormality, Heart in 19 studies
Potassium Chloride: A white crystal or crystalline powder used in BUFFERS; FERTILIZERS; and EXPLOSIVES. It can be used to replenish ELECTROLYTES and restore WATER-ELECTROLYTE BALANCE in treating HYPOKALEMIA.
potassium chloride : A metal chloride salt with a K(+) counterion.
| Excerpt | Relevance | Reference |
|---|---|---|
| "33." | 2.87 | Role of terminal warm blood cardioplegia in complex congenital heart surgery. ( Boom, CE; Busro, PW; Jusuf, AA; Rachmat, J; Romolo, H; Sadikin, M; Santoso, A; Sastroasmoro, S; Suwarto, S, 2018) |
| "From June 1995 to July 1997, we treated 32 congenital heart disease patients using Bretschneider cardioplegic solution and 20 patients using blood cardioplegia." | 1.30 | [Single-dose and high-volume Bretschneider cardioplegic solution for congenital heart surgery]. ( Asano, H; Kobayashi, J; Kobayashi, T; Koike, K; Kyo, S; Ogiwara, M; Omoto, R; Taketazu, M; Tsunemoto, M; Yokote, Y, 1999) |
| "A total of 31 pediatric cardiac patients (mean age 19 1/2 months) who required surgery for repair of various congenital heart defects were prospectively studied in the postoperative period to determine potassium (K) dose-response characteristics." | 1.27 | Intravenous KCl supplementation in pediatric cardiac surgical patients. ( Bessinger, FB; Katkov, H; Schaber, DE; Singh, A; Stone, FM; Uden, DL, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (36.84) | 18.7374 |
| 1990's | 3 (15.79) | 18.2507 |
| 2000's | 1 (5.26) | 29.6817 |
| 2010's | 6 (31.58) | 24.3611 |
| 2020's | 2 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| Haranal, M | 1 |
| Chin, HC | 1 |
| Sivalingam, S | 1 |
| Raja, N | 1 |
| Mohammad Shaffie, MS | 1 |
| Namasiwayam, TK | 1 |
| Fadleen, M | 1 |
| Fakhri, N | 1 |
| Caneo, LF | 1 |
| Matte, GS | 1 |
| R Turquetto, AL | 1 |
| Pegollo, LMC | 1 |
| Amato Miglioli, MC | 1 |
| T de Souza, G | 1 |
| Amato, LP | 1 |
| Miana, LA | 1 |
| B Massoti, MR | 1 |
| Penha, JG | 1 |
| Tanamati, C | 1 |
| Jatene, MB | 1 |
| Jatene, FB | 1 |
| Li, J | 1 |
| Wu, Y | 1 |
| Tian, X | 1 |
| Wang, J | 1 |
| Dong, M | 1 |
| Wang, A | 1 |
| Ma, S | 1 |
| Busro, PW | 1 |
| Romolo, H | 1 |
| Sastroasmoro, S | 1 |
| Rachmat, J | 1 |
| Sadikin, M | 1 |
| Santoso, A | 1 |
| Boom, CE | 1 |
| Suwarto, S | 1 |
| Jusuf, AA | 1 |
| Valente, AS | 1 |
| Lustosa, GP | 1 |
| Mota, LAM | 1 |
| Lima, A | 1 |
| Mesquita, FA | 1 |
| Gondim, A | 1 |
| Rodrigues, FA | 1 |
| Pompeu, RG | 1 |
| Branco, KC | 1 |
| Bojan, M | 1 |
| Peperstraete, H | 1 |
| Lilot, M | 1 |
| Tourneur, L | 1 |
| Vouhé, P | 1 |
| Pouard, P | 1 |
| Ma, C | 1 |
| Shen, DR | 1 |
| Zhang, Q | 1 |
| Meng, XC | 1 |
| Wang, YX | 1 |
| Peng, L | 1 |
| Meng, BY | 1 |
| Li, XW | 1 |
| Lin, YZ | 1 |
| Lin, H | 1 |
| Huang, JB | 1 |
| Tang, XM | 1 |
| Long, XM | 1 |
| Lu, WJ | 1 |
| Wen, ZK | 1 |
| Liang, J | 1 |
| Li, DY | 1 |
| Zhao, XF | 1 |
| Young, D | 1 |
| Fox, ML | 1 |
| Burrows, FA | 1 |
| Reid, RW | 1 |
| Hickey, PR | 1 |
| Laussen, PC | 1 |
| Hansen, DD | 1 |
| Young, JN | 1 |
| Choy, IO | 1 |
| Silva, NK | 1 |
| Obayashi, DY | 1 |
| Barkan, HE | 1 |
| Asano, H | 1 |
| Kyo, S | 1 |
| Ogiwara, M | 1 |
| Tsunemoto, M | 1 |
| Yokote, Y | 1 |
| Omoto, R | 1 |
| Koike, K | 1 |
| Kobayashi, T | 1 |
| Kobayashi, J | 1 |
| Taketazu, M | 1 |
| Di Summa, M | 1 |
| Carletta, C | 1 |
| Morea, M | 1 |
| Ratcliffe, JM | 1 |
| Wyse, RK | 1 |
| Hunter, S | 1 |
| Alberti, KG | 1 |
| Elliott, MJ | 1 |
| Schaber, DE | 1 |
| Uden, DL | 1 |
| Stone, FM | 1 |
| Singh, A | 1 |
| Katkov, H | 1 |
| Bessinger, FB | 1 |
| Fluharty, AL | 1 |
| Scott, ML | 1 |
| Porter, MT | 1 |
| Kihara, H | 1 |
| Wilson, MG | 1 |
| Towner, JW | 1 |
| Nouaille, J | 1 |
| Solov'ev, GM | 1 |
| Radzivil, GG | 1 |
| Mikheeva, EV | 1 |
| Krohn, BG | 1 |
| Urquhart, RR | 1 |
| Magidson, O | 1 |
| Tsuji, HK | 1 |
| Redington, JV | 1 |
| Kay, JH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Custodiol Versus Blood Cardioplegaia in Paediatric Cardiac Surgery[NCT03082716] | Phase 2 | 49 participants (Actual) | Interventional | 2016-03-16 | Completed | ||
| Attenuation of Myocardial Dysfunction by N-Acetylcysteine in Infants Undergoing Arterial Switch Procedure[NCT00374088] | Phase 2 | 21 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| Custodiol-HTK Solution as a Cardioplegic Agent- A Prospective Non-Inferiority Randomized Clinical Trial[NCT01681095] | Phase 2 | 110 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Maximum serum creatinine over first 3 days postoperative. (NCT00374088)
Timeframe: 72 hours
| Intervention | mg/dL (Mean) |
|---|---|
| Placebo | 0.99 |
| N-acetylcysteine | 0.74 |
Serial cardiac output was measured by thermodilution. The outcome of maximum decline in indexed cardiac output from 1 hour postoperative to lowest output within 24 hours postoperative was then calculated and compared between NAC and placebo groups. (NCT00374088)
Timeframe: 24 hours
| Intervention | L/min/m2 (Mean) |
|---|---|
| Placebo | 0.68 |
| N-acetylcysteine | 0.29 |
Total urine output over the first 24 hours postoperative (NCT00374088)
Timeframe: 24 hours
| Intervention | mL (Mean) |
|---|---|
| Placebo | 96 |
| N-acetylcysteine | 176 |
Number of participants with all-cause mortality AS reported in the Society of Thoracic Surgeons (STS) database after 30 days postoperative (NCT01681095)
Timeframe: 30 days post procedure
| Intervention | participants (Number) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 0 |
| Cold Blood Cardioplegia | 0 |
CK-MB measured 24 hours post-operatively (NCT01681095)
Timeframe: 24 hours post procedure
| Intervention | ng/mL (Mean) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 20 |
| Cold Blood Cardioplegia | 24 |
CK-MB measured 48 hours post-operatively (NCT01681095)
Timeframe: 48 hours post procedure
| Intervention | ng/mL (Mean) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 6.0 |
| Cold Blood Cardioplegia | 7.8 |
CK-MB measured pre-operatively (NCT01681095)
Timeframe: pre-operative
| Intervention | ng/mL (Mean) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 1.9 |
| Cold Blood Cardioplegia | 2.6 |
Number of participants with new or worsening of cardiac dysrhythmias (NCT01681095)
Timeframe: up to 36 hrs post surgery
| Intervention | participants (Number) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 24 |
| Cold Blood Cardioplegia | 30 |
Troponin-I measured 24 hours post-operative (NCT01681095)
Timeframe: 24 hours post procedure
| Intervention | ng/mL (Mean) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 5.7 |
| Cold Blood Cardioplegia | 7.8 |
Troponin-I measured 48 hours post-operative (NCT01681095)
Timeframe: 48 hours post procedure
| Intervention | ng/mL (Mean) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 3.0 |
| Cold Blood Cardioplegia | 4.8 |
Troponin-I measured pre-operatively (NCT01681095)
Timeframe: pre-operatively
| Intervention | ng/mL (Mean) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | .03 |
| Cold Blood Cardioplegia | .03 |
Number of participants with cardiovascular-related mortality AS reported in the Society of Thoracic Surgeons (STS) database after 30 days postoperative (NCT01681095)
Timeframe: 30 days post procedure
| Intervention | participants (Number) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 0 |
| Cold Blood Cardioplegia | 0 |
Creatine phosphokinase MB isoenzyme (CK-MB) difference from baseline 7 hours post surgery (NCT01681095)
Timeframe: Baseline and 7 hours post surgery
| Intervention | ng/mL (Median) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 18.8 |
| Cold Blood Cardioplegia | 22.2 |
Troponin I values, difference from baseline 7 hours post surgery (NCT01681095)
Timeframe: Baseline and 7 hours post surgery
| Intervention | ng/mL (Median) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 9.65 |
| Cold Blood Cardioplegia | 10.15 |
LV ejection fraction by TTE, difference from baseline at 24 hours post surgery (NCT01681095)
Timeframe: Baseline and 24 hours post surgery
| Intervention | % LV volume (Mean) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | -0.06 |
| Cold Blood Cardioplegia | 1.9 |
Total time in minutes on any vasopressor or inotropic agent, including norepinephrine, epinephrine, vasopressin, milrinone, dobutamine, dopamine and/or neo-synephrine (NCT01681095)
Timeframe: up to 36 hours post procedure
| Intervention | minutes (Median) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 340 |
| Cold Blood Cardioplegia | 582 |
Duration of stay in ICU, from ICU admission to ICU discharge (NCT01681095)
Timeframe: up to 100 days after admission
| Intervention | days (Median) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 3 |
| Cold Blood Cardioplegia | 3 |
Number or participants fulfilling at least two of the following 3 criteria: (1) CK-MB of 100 ug/L or more and/or troponin-I of 3.0 ug/L or more, (2) appearance of new postoperative Q waves on the EKG of more than 0.03 seconds, and (3) a new hypokinetic or akinetic area in the left or right ventricle by echocardiography. (NCT01681095)
Timeframe: up to 36 hours post procedure
| Intervention | participants (Number) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 0 |
| Cold Blood Cardioplegia | 0 |
Number of patients receiving vasopressor or inotropic infusion for greater than 20 minutes in the operating room, including norepinephrine, epinephrine, vasopressin, milrinone, dobutamine, dopamine and/or neo-synephrine. (NCT01681095)
Timeframe: during operative procedure
| Intervention | participants (Number) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 47 |
| Cold Blood Cardioplegia | 43 |
time in hours from intubation to extubation, with intervening transport to the cardiac critical care unit. (NCT01681095)
Timeframe: up to 36 hours post procedure
| Intervention | hours (Median) |
|---|---|
| Cardioplegia: Custodiol HTK Solution | 10.5 |
| Cold Blood Cardioplegia | 11.4 |
6 trials available for potassium chloride and Abnormality, Heart
| Article | Year |
|---|---|
Safety and Effectiveness of Del Nido Cardioplegia in Comparison to Blood-Based St. Thomas Cardioplegia in Congenital Heart Surgeries: A Prospective Randomized Controlled Study.
Topics: Cardioplegic Solutions; Cardiopulmonary Bypass; Child, Preschool; Electrolytes; Female; Heart Arrest | 2020 |
Role of terminal warm blood cardioplegia in complex congenital heart surgery.
Topics: Apoptosis; Arrhythmias, Cardiac; Biomarkers; Cardiac Output, Low; Cardioplegic Solutions; Caspase 3; | 2018 |
Comparative Analysis of Myocardial Protection with HTK Solution and Hypothermic Hyperkalemic Blood Solution in the Correction of Acyanogenic Congenital Cardiopathies - A Randomized Study.
Topics: Analysis of Variance; Cardioplegic Solutions; Creatine Kinase, MB Form; Double-Blind Method; Echocar | 2019 |
[Protective effect of cold autologous blood cardioplegic solution on the heart of infants with cyanotic congenital heart disease].
Topics: Cardioplegic Solutions; Cardiopulmonary Bypass; Energy Metabolism; Female; Glucose; Heart Defects, C | 2013 |
Antegrade cold blood cardioplegia is not demonstrably advantageous over cold crystalloid cardioplegia in surgery for congenital heart disease.
Topics: Bicarbonates; Blood; Calcium Chloride; Cardioplegic Solutions; Child, Preschool; Female; Heart Arres | 1997 |
The role of the priming fluid in the metabolic response to cardiopulmonary bypass in children of less than 15 kg body weight undergoing open-heart surgery.
Topics: Blood Glucose; Blood Proteins; Cardioplegic Solutions; Cardiopulmonary Bypass; Electrolytes; Glucona | 1988 |
13 other studies available for potassium chloride and Abnormality, Heart
| Article | Year |
|---|---|
Initial experience with del Nido cardioplegia solution at a Pediatric and Congenital Cardiac Surgery Program in Brazil.
Topics: Brazil; Cardiac Output, Low; Cardiac Surgical Procedures; Cardioplegic Solutions; Child; Electrolyte | 2022 |
Protective effect of HTK solution on postoperative pulmonary function in infants with CHD and PAH.
Topics: Cardiopulmonary Bypass; Child, Preschool; Female; Glucose; Heart Defects, Congenital; Humans; Hypert | 2017 |
Cold histidine-tryptophan-ketoglutarate solution and repeated oxygenated warm blood cardioplegia in neonates with arterial switch operation.
Topics: Blood Transfusion; Cardiac Surgical Procedures; Cardioplegic Solutions; Coronary Vessels; Female; Fo | 2013 |
Histidine-tryptophan-ketoglutarate solution decreases mortality and morbidity in high-risk patients with severe pulmonary arterial hypertension associated with complex congenital heart disease: an 11-year experience from a single institution.
Topics: Analysis of Variance; Cardioplegic Solutions; Cardiopulmonary Bypass; Child, Preschool; Female; Gluc | 2016 |
Shortage of pharmacists may have contributed to patient's death.
Topics: Fatal Outcome; Heart Defects, Congenital; Humans; Infant, Newborn; Medication Errors; New York City; | 2002 |
The influence of cardiopulmonary bypass on ionized magnesium in neonates, infants, and children undergoing repair of congenital heart lesions.
Topics: Adolescent; Adult; Arrhythmias, Cardiac; Bicarbonates; Calcium Chloride; Cardioplegic Solutions; Car | 1997 |
[Single-dose and high-volume Bretschneider cardioplegic solution for congenital heart surgery].
Topics: Cardiac Surgical Procedures; Cardioplegic Solutions; Child, Preschool; Glucose; Heart Arrest, Induce | 1999 |
[Myocardial protection from cardioplegic and hypothermia during aortic cross-clamping (author's ttrans)].
Topics: Adenosine Triphosphate; Aorta; Calcium Chloride; Cardiac Surgical Procedures; Constriction; Coronary | 1979 |
Intravenous KCl supplementation in pediatric cardiac surgical patients.
Topics: Adolescent; Adult; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Heart Defects, | 1985 |
Acid -glucosidase in amniotic fluid.
Topics: Amniotic Fluid; Carbon Isotopes; Cardiomegaly; Clinical Enzyme Tests; Disaccharides; Drug Stability; | 1973 |
[Medical treatment of heart failure in infants and young children].
Topics: Anti-Bacterial Agents; Anticoagulants; Aortic Coarctation; Bradycardia; Chlorothiazide; Diet, Sodium | 1969 |
[Treatment of potassium balance disturbances by parenteral administration of large doses of potassium chloride in patients operated upon under conditions of extracorporeal circulation. 2].
Topics: Diuresis; Electrocardiography; Extracorporeal Circulation; Heart Defects, Congenital; Humans; Hypoka | 1969 |
Metabolic alkalosis following heart surgery.
Topics: Alkalosis; Blood Urea Nitrogen; Carbon Dioxide; Cardiac Surgical Procedures; Chlorides; Extracorpore | 1968 |